Therefore, the treatment with IFN-γ/TNF-α enabled T-sMs to induce anti-tumor function of the neutrophils by increasing the production and/or release of MPO, NE, and TRAIL, and reducing the expression of Bv8 and Mmp9 genes. The gene discussed is TNFSF10; the disease is neoplasm.